Nadim Ahmed, Cullinan Therapeutics CEO
In latest turn to autoimmune therapies, Cullinan nabs $280M to join lupus space
At Cullinan, immunology is quite literally the new oncology.
The biotech announced Tuesday that it’s expanding its pipeline from cancer to include immunology and changing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.